Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

VYNE Therapeutics (VYNE) Receivables - Net (2017 - 2023)

VYNE Therapeutics (VYNE) has disclosed Receivables - Net for 7 consecutive years, with $250000.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Receivables - Net fell 46.92% year-over-year to $250000.0, compared with a TTM value of $250000.0 through Sep 2023, down 46.92%, and an annual FY2022 reading of $173000.0, down 97.72% over the prior year.
  • Receivables - Net was $250000.0 for Q3 2023 at VYNE Therapeutics, up from $234000.0 in the prior quarter.
  • Across five years, Receivables - Net topped out at $15.8 million in Q4 2020 and bottomed at $105000.0 in Q1 2023.
  • Average Receivables - Net over 5 years is $5.2 million, with a median of $3.5 million recorded in 2020.
  • The sharpest move saw Receivables - Net surged 11617.78% in 2020, then plummeted 97.72% in 2022.
  • Year by year, Receivables - Net stood at $135000.0 in 2019, then soared by 11617.78% to $15.8 million in 2020, then plummeted by 52.06% to $7.6 million in 2021, then tumbled by 97.72% to $173000.0 in 2022, then soared by 44.51% to $250000.0 in 2023.
  • Business Quant data shows Receivables - Net for VYNE at $250000.0 in Q3 2023, $234000.0 in Q2 2023, and $105000.0 in Q1 2023.